Recommended

Sarepta’s DMD drug Elevidys issued FDA label update
Rare disease gene therapy granted European first approval
Johnson & Johnson agrees $3bn oncology acquisition
European Commission grants EU first for J&J’s Simponi biosimilar
Researchers validate approach that supports animal-based pyrogen test replacement
ON DEMAND webinar: automating QC testing for radiopharmaceutical production
Insmed secures EU approval for Brinsupri (brensocatib)
Moderna invests over $140m to onshore mRNA medicine manufacturing in US

List view / Grid view

News

Pierre Fabre Pharmaceuticals starts Phase IIa trial for F17464
Pierre Fabre Pharmaceuticals starts Phase IIa trial for F17464

Pierre Fabre Pharmaceuticals announce initiation of Phase IIa clinical trial program for F17464 in schizophrenia

3 February 2015 | By Pierre Fabre Pharmaceuticals

Pierre Fabre Pharmaceuticals has announced the initiation of a Phase IIa clinical trial program for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The six-week multinational European trial…

Afrezza® (insulin human) Inhalation Powder
Afrezza® (insulin human) Inhalation Powder

Sanofi and MannKind announce Afrezza®, the only inhaled insulin, now available in the U.S.

3 February 2015 | By Sanofi / MannKind Corporation

Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes...